CCO Oncology Podcast
Un podcast de Clinical Care Options
Catégories:
185 Épisodes
-
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
Publié: 22/10/2024 -
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations
Publié: 16/10/2024 -
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Publié: 01/10/2024 -
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
Publié: 30/09/2024 -
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC
Publié: 06/09/2024 -
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
Publié: 05/09/2024 -
ROS1-Alterations and Molecular Testing in Advanced NSCLC
Publié: 28/08/2024 -
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Publié: 05/08/2024 -
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Publié: 22/07/2024 -
Current Clinical Practice and NCCN Guidelines for CLL/SLL
Publié: 18/07/2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
Publié: 12/07/2024 -
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
Publié: 11/07/2024 -
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Publié: 09/07/2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for AML
Publié: 08/07/2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
Publié: 05/07/2024 -
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
Publié: 14/05/2024 -
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Publié: 07/05/2024 -
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
Publié: 28/03/2024 -
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
Publié: 18/03/2024 -
Current Considerations for Adverse Event Management With HER3-Directed Agents
Publié: 26/12/2023
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
